Colorectal cancer
Conditions
Interventions
In the tested group, after the radiological placement of port and catheter system, hepatic arterial infusion using 5FU is performed within 6 months at the longest, and then FOLFOX+Bevacizumab therapy
Sponsors
Japan Interventional Radiology in Oncology Study Group (JIVROSG)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)pathologically confirmed colorectal cancer 2)ALP more than 600 IU/L and unresectable liver metastases 3)No prior treatment using L-OHP or Bevacizumab 4)20 years old or more 5)Performance status (ECOG):0-2 6)No mtter of measurable lesion 7)Previous chemotherapy as folloes; - No prior chemotherapy - Chemotherapy of fluoropyrimidines for less than 2 weeks - Previous adjuvant chemotherapy of fluoropyrimidines with more than 6 months interval to the recurrence, and no previous chemotherapy to the recurrence 8)Within normal function of major organs 9)More than 8 weeks survival expected 10)Written informed consent
Exclusion criteria
Exclusion criteria: 1)Massive pleural effusion or ascites 2)Bleeding of digestive organ 3)Uncontrolled active infection 4)Severe complications (ileus, interstitial pneumonia, uncontrolled-diabetis, cardiac failure, renal failure, liver cirrhosis, liver failure- 5)Active other malignancy 6)Phsicological disorder 7)Pregnancy or lactation 8)Positive HBs 9)Severe allergy to iodine contrast medium 10)Bone metastases requiring local treatment 11)Brain metastasis or suspiciou brain metastasis 12)Thrombosis or Embolism within 1 year 13)Grade 2 or more sensory disturbance (CTCAEv3.0) 14)Requiring anti-thrombogenic therapy to prevent thrombosis 15)Unsuitable by physician's decision
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall survival period | — |
Secondary
| Measure | Time frame |
|---|---|
| Adverse events Time to treatment failure | — |
Countries
Japan
Contacts
Public ContactTakashi Ura
Aichi Cancer Center Hospital Department of Medical oncology
Outcome results
None listed